Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

An estimated 450,000 people in Ireland currently have asthma, with approximately 900,000 individuals expected to develop the condition over their lifetime